Background: Identifying unwarranted variation in health care can highlight opportunities to reduce harm. One often discretionary process in oncology is use of implanted ports to administer intravenous chemotherapy. While there are benefits, ports carry risks. This study's objective was to assess provider-driven variation in port use among cancer patients receiving chemotherapy.
I dentifying unwarranted variation in health care can highlight opportunities for improvement. Variation in practice has long been documented at the physician, group practice, institution, and regional levels. [1] [2] [3] [4] [5] [6] Yet, for specific health care processes that carry risks but are discretionary, tendencies for providers to use or to not use them have not been extensively studied. By recognizing and documenting these tendencies, we can help to identify likely users and target interventions to these providers to help reduce the use of risky processes under discretionary circumstances.
One process in oncology that is potentially risky and often discretionary is the use of implanted ports. Implanted ports are devices placed under the skin to enable venous access to administer intravenous (IV) treatments such as chemotherapy. 7 For some patients, an acceptable alternative is a temporary IV catheter.
Ports can have benefits to patients and clinicians. The port is easy to maintain and provides ready venous access for patients with difficult to access veins or those receiving therapy over long periods of time. 8 It can also facilitate outpatient administration of chemotherapy and other treatments. For common diseases like colon cancer, it can support continuous chemotherapy infusion, which can result in fewer toxicities compared with bolus administration. 9 Ports have the advantage of ready, convenient venous access, and may reduce discomfort and anxiety associated with repeated venous punctures. They have been shown to be largely accepted by patients who have them, particularly for those who did not experience complications. 8, 10, 11 Temporary IV catheters can take nurses time to insert and have a risk of extravasation. 12 Despite the benefits of using ports, they also have disadvantages that providers should consider in decision making. The main disadvantage is that port use is associated with complications such as infections and thromboses, which may result in chemotherapy delays, costs, or morbidity. 7, 8, 13, 14 Port implantation also involves a minor surgical procedure that carries risks. Although the port is often removed after completion of chemotherapy, many patients develop a scar on the upper chest, which may cause emotional distress. 8 In 1 randomized study of ports versus temporary IV catheter use, port use was shown to reduce discomfort, but did not have benefits to overall quality of life. 11 Despite known complications, guidelines for the selection of a venous access device are vague. The decision is often left to the provider. Current US guidelines primarily focus on catheter maintenance, selection of the appropriate insertion site, and prevention of complications. 7, [15] [16] [17] Given the lack of specification for matching patients to an appropriate venous access device when several choices are available, providers may have personal tendencies that dominate their decisions to use or not to use ports. Their personal experiences, the characteristics of their practices, incentives, convenience, or patient preferences may influence provider tendencies. The American Society of Clinical Oncology (ASCO) Clinical Practice Guidelines Committee recommends further research to assess the use of such chemotherapy administration methods in practice. 7 If port use varies among providers as suspected, irrespective of patient factors, it may signal an opportunity to standardize care to maximize patient benefit.
The objective of this study was to assess provider-driven variation in port use for cancer patients receiving chemotherapy. If there is evidence of potentially unwarranted variation, it suggests opportunities to standardize care to maximize patient benefit and reduce harm. We hypothesized that providers' past behavior would predict their future behavior, supporting the idea that providers have tendencies to use or not to use such services. We also hypothesized that patients receiving chemotherapy in the hospital outpatient facility setting would be less likely to have a port implanted than patients receiving chemotherapy in the physicians' office setting. Physicians in office-based settings may be more responsive to incentives or the need for convenience. 18 
METHODS

Data Source
We analyzed population-based SEER-Medicare data to assess differences in port use across health care providers of older adult patients with cancer, diagnosed 2005-2007. The SEER-Medicare database contains information from 2 linked population-based sources of data primarily on people aged 65 years or older with cancer: the Surveillance Epidemiology and End Results (SEER) cancer registries and Medicare enrollment and claims files. The National Cancer Institute (NCI)-sponsored SEER program includes several states and registries, covering approximately 28% of the US population. 19 The SEER registries collect information on site and extent of disease, first course of cancer-directed therapy, and sociodemographic characteristics, with active follow-up for date and cause of death. For patients age 65 and over, SEER records have been linked to Medicare claims. Compared with the US older adult population, the SEER-Medicare population has a similar age and sex distribution, a slightly higher proportion of individuals living in urban and high-income areas, and a smaller proportion of nonwhite individuals. 19 
Study Sample
The study sample included patients ages 66 years or older who received cancer-directed surgery for breast, colorectal, lung, or pancreas cancers within 1 year of diagnosis and began chemotherapy treatment within 1 year following surgery. 20, 21 We included those at least age 66 to allow for a full year of prediagnosis claims data. Patients were diagnosed between 2005, the first year of more detailed Current Procedural Terminology (CPT) codes for port use, and 2007. 22, 23 We examined each patient's Medicare claims before the start of chemotherapy. We excluded patients who did not receive cancer-directed surgery. These patients were more likely to have known advanced disease that would require extended chemotherapy use.
We excluded patients who were enrolled in an HMO or who had incomplete Medicare coverage from the year before diagnosis through 2 years after diagnosis, or whose cancer diagnosis was made only at the time of death. We also excluded patients who only had chemotherapy claims from the inpatient setting, and patients who had a claim for hemodialysis within 2 years after their cancer diagnosis to focus on port use for chemotherapy administration.
Variables and Outcomes
The following patient, disease, and treatment characteristics from SEER and Medicare records were included in our analyses: age, sex, race, a modified Charlson comorbidity index (based on all inpatient, outpatient, and physician claims from 1 y before diagnosis), 24,25 marital status, median income of Census tract of residence, geographic region, metropolitan location, stage, prior cancer, year of diagnosis, and radiation therapy. 26 To assign patients to a setting of care delivery, we used the source of their chemotherapy claims: hospital outpatient file or the National Claims History (NCH) file (physicians' office). 27 We assigned patients with both NCH and hospital outpatient claims (14%) to the source of their first chemotherapy claim. This approach was highly consistent with an alternative approach that classified setting by the majority of chemotherapy claims rather than the first claim. We assigned patients to a specific provider based on the first chemotherapy claim. For this analysis, claims after May 2007 were not examined because the National Provider Identifier replaced the Unique Physician Identifier Number as the required identifier for Medicare services and a crosswalk was not available at the time of this analysis.
We identified port insertion based on CPT codes (Appendix Table 1 , Supplemental Digital Content 1, http:// links.lww.com/MLR/A941). We exclusively included port insertion before the initiation of chemotherapy, given that port use is more likely to be discretionary during this time interval compared with after treatment begins. 11 
Statistical Analyses
For patients receiving treatment from hospital outpatient facilities compared with those receiving treatment from physicians' offices, we assessed whether there were differences in the proportion of patients who had ports before the initiation of chemotherapy. We used w 2 statistics to compare cohort characteristics by setting. We used unadjusted and adjusted logistic regression to evaluate the association between the setting of care and the likelihood of port insertion. Adjusted models included patient, disease, and treatment characteristics.
Our main analysis focused on assessing individual provider variation in use of ports. One of the challenges in examining providers' practice patterns and variation between providers can be the limited number of eligible patients per provider. 28 Considering this challenge, we sought to assess whether providers' prior behavior would predict their future behavior and thus help to reveal practice patterns. We studied whether implanting a port in a given patient increases the likelihood that a provider will implant a port in the following patient. The underlying premise is that, in providers with high frequencies of port insertion, a patient with insertion is more likely to be preceded by a patient with insertion; the converse is true for providers with low frequencies of port insertion. This premise leads to a positive test of association between prior and future use of port. We chronologically ordered patients assigned to each provider by chemotherapy start date and then identified pairs of consecutive patients. We used a logistic model, adjusted for patient demographic, disease, and treatment characteristics, year of diagnosis, and treatment setting. We estimated the probability of a patient receiving a port as a function of port use by the provider's prior patient.
The primary physician decision maker for port use is unknown in this dataset, and could be a medical oncologist, a surgeon, or both. In our main analysis, we used the provider associated with the first chemotherapy claim, assumed to be a medical oncologist. We also conducted a sensitivity analysis where we assigned each patient to the surgeon who performed his or her cancer-directed surgery. For this analysis we ordered surgeons' patients by surgery date.
To assess another dimension of provider variation, we conducted an additional analysis for high-volume providers, defined as those with Z10 patients assigned. For this subset of providers, we assessed the extent of variation in port use between individual providers using a nonlinear random-effects model with logit link function. This approach models the logit probability of port insertion as a linear function of patient demographic, disease, and treatment variables, and a random provider effect. [29] [30] [31] [32] This model explicitly incorporates the assumption that underlying tendencies in providers' behavior lead to differences in port insertion rates. A test of whether the estimated variance of the random effects is significantly different from zero provides indication of significant unexplained variation across providers. Furthermore, providers whose estimated random effects are significantly different from zero are identified as outliers.
All analyses were conducted separately by cancer site to account for differences between patients and treatments. Analyses were performed in SAS (Version 9.2, Cary, NC). We considered a 2-sided P-value <0.05 to be statistically significant. NCI approved the use of the SEER-Medicare database for this study, which was deemed exempt by the MSK Institutional Review Board. The funding source had no role in the study.
RESULTS
The study cohort included >18,000 patients with breast cancer (N = 6591), colorectal cancer (N = 7590), lung cancer (N = 3300), or pancreatic cancer (N = 971) ( Table 1) . Patients who received chemotherapy in physicians' offices and those who received chemotherapy in hospital outpatient facilities had similar disease profiles in general, but differed by certain patient demographic characteristics. For example, higher percentages of nonwhite patients and patients in Census tracts with lower median incomes were seen in hospital outpatient facilities (Appendix Table 2 , Supplemental Digital Content 2, http://links.lww.com/MLR/A942).
In each of the 4 cancer sites, patients who received chemotherapy in hospital outpatient facilities were less likely to receive a port than patients who received chemotherapy in physicians' offices, independent of demographic, disease, and treatment characteristics. The adjusted odds ratio (AOR) varied from 0.50 to 0.75 across cancer sites ( Table 2 ).
The likelihood of port insertion in a given patient was related to the use of a port in a provider's previous patient receiving chemotherapy (Table 3 ). Of the 2836 unique providers in the sample, 62% (N = 1679) were identified as the accountable provider for at least 2 patients in the dataset. Over 71% of accountable physicians had specialty codes listed as oncology, hematology, or internal medicine. When a provider's last patient received a port, the next patient was about twice as likely to receive a port than if the provider's last patient did not (AORs from 1.71 to 2.25, P < 0.001 for all cancers). This finding held when combining cancer types and when stratified by setting. Setting remained a significant predictor of port use in the combined model. The predicted probability of port use was higher for patients whose provider's prior patient received a port compared with those whose provider's prior patient did not, in both treatment settings (Table 4 ). When we reassigned the decision maker as the patient's surgeon, we found similar results; when a surgeon's prior patient received a port, the next patient was more likely to receive a port than if the surgeon's prior patient did not.
An analysis of the 354 providers (12% of all providers in the sample) who were accountable for at least 10 patients suggested residual between-provider variation in the likelihood of port insertion, adjusted for patient demographic, disease, and treatment characteristics (P < 0.0001). Fiftyseven physicians (16%) were identified as outliers, indicating an increased propensity toward port insertion, beyond what was explained by their patients' characteristics.
DISCUSSION
In this study of older adults who received chemotherapy for 1 of 4 common cancers, a provider's prior behavior was strongly associated with future behavior regarding the likelihood of inserting a port for delivery of cancer chemotherapy. This result held when accounting for patient characteristics. Findings from a random effects model also demonstrated between-provider variation in port use. Collectively, these findings support our hypothesis that providers have certain tendencies to use or not to use ports for chemotherapy administration.
Given our observations and those from prior studies demonstrating complications associated with port use, 7, 13, 33 some of the observed use of implanted ports in our dataset is likely unwarranted. As such, there may be room for standardization to ensure an appropriate match between the method of chemotherapy administration and the patient. Certainly, for some patients, port use is necessary or preferred. 8, 10, 11 But for other patients, the expected costs and harms may outweigh the benefits. 11 It will be important to better understand the drivers of providers' decision making to influence their behavior and develop effective initiatives to reduce unwarranted use. Initiatives might include developing more explicit standards for selecting appropriate patients for port use, developing relevant quality measures, and providing feedback to individual providers. It also might be achieved by aligning financial incentives with desired behavior, such as through episode-based payment models. 34 Future research to assess patient and cost outcomes related to the practice variation observed can also help to optimize decision making.
This study also highlights the potentially meaningful impact of the setting of chemotherapy administration on port use. 27 The effect of treatment setting remained significant, even after accounting for a provider's prior behavior. We found differences in patient case-mix between those receiving chemotherapy in hospital outpatient facilities compared with physicians' offices, which have been identified previously. 27 But after taking these characteristics into account, the differences in port use by setting remained. Setting effects may reflect unmeasured differences in patient characteristics or provider factors, such as those that relate to responsiveness to financial incentives. 27 In a study examining the influence of changes in chemotherapy payment on ordering behavior, the authors found that the physicians' office setting was more responsive to changes in incentives than hospital outpatient facilities. 27 In our example, the port insertion procedure is associated with payment (Medicare reimbursement of $1198 for physicians' office procedure) as well. 35 Compared with hospital outpatient facilities, physicians' offices may also not have as many skilled nurses available for temporary IV catheter insertions, the nurses may have higher workloads, or the nurses may fear ex-travasation. 36 The reasons for the observed differences between settings are unknown and will require further study. Our approach to examining provider practice patterns builds on the existing literature that demonstrates that providers may have tendencies toward providing certain services. 5, 6, 37, 38 Findings from this study demonstrate that provider tendencies are highly predictive of future behavior in the context of use of ports for chemotherapy administration. Our approach assessing the predictive value of providers' prior behavior can reveal provider-level tendencies and can help to assess the use of other services that might be overused or used often under discretionary circumstances. Examples might include routine follow-up tests, screening, referrals to specialists, or hospitalizations for common conditions. 38 Identifying likely users of these services can help direct interventions to reduce overuse to those at highest risk of unwarranted use. In the case of implanted ports, it would include providers who have used the service for a prior patient.
Our examination of variation in provider practice confirms the difficulty of making inferences about individual providers' tendencies when most providers have very low patient volume. In this setting, traditional approaches to examine between-provider variability such as random effects models lead to unstable results. Providers with small sample sizes are moved toward the population average, resulting in limited sensitivity to detect unusual practices. 39, 40 On the basis of our analysis restricted to providers with Z10 patients, we found evidence of unexplained variation between providers' use of port. However, only 13% of all providers (having 25% of all patients assigned to them) met the threshold for inclusion, raising questions about the generalizability of these results. We propose that the magnitude of the association between port insertion in a prior and a future patient is directly related to interprovider variability and can serve to estimate this variability while making more efficient use of the available data. The properties of this proposed relationship warrant further study.
There may be other unmeasured associated factors that contributed to the observed variation in port receipt and provider practice patterns. There are circumstances in which port use would be considered clinically appropriate such as when the patient has difficult to access veins and venous access is needed on an ongoing basis. 7 In this analysis we did not consider the specific chemotherapy agents and regimens. We were interested in assessing variation in port use between settings and providers and the predictive value of prior use. While chemotherapy selection may be in part provider driven, chemotherapy options available for the patient population of interest should not be a function of the provider or setting. We accounted for patient demographic, disease, and treatment characteristics, and our main findings were consistent across cancer types.
Several limitations of our dataset should be noted. If multiple providers were involved in a patient's care and treatment decisions, our assignment of a single accountable provider to each patient may have been imprecise. We assigned patients to the provider associated with their first chemotherapy claim, and this approach yielded similar as- Provider's prior patient received a port 0.575 Provider's prior patient did not receive a port 0.388 *Predicted probability that an individual patient will receive a port given the setting and use of a port by the provider's prior patient, adjusted for age, sex, race, a modified Charlson comorbidity index, marital status, median income of Census tract of residence, geographic region, metropolitan location, stage, prior cancer, year of diagnosis, radiation therapy before chemotherapy. signments as an approach based on the majority of chemotherapy claims. We also conducted a sensitivity analysis where we reassigned the patient's decision maker as his or her surgeon. Results were similar. While some patients may be incorrectly classified as having a port, it is unlikely that it would be systematic or influence the results. Codes for port insertion were updated in 2004 because of concerns about specificity; these updates may temper concerns. 22, 23 This study only included information from patients who are ages 66 years and older, and it is not clear whether providers' tendencies and setting-specific patterns differ in younger patients.
In patients receiving chemotherapy, port use was less likely for those treated in the hospital outpatient facility setting compared with the physicians' office setting. At the provider level, port insertion in a patient was a strong predictor of the likelihood of insertion in the next patient treated. These patterns suggest provider-driven behavior, which demonstrate an opportunity for standardization in the use of ports for chemotherapy administration. They also support future exploration of physician tendencies to use or not to use services that are commonly overused. Identifying likely users can inform the development of targeted interventions to increase appropriate use and reduce unwarranted variation.
